最高15.3亿美元！中国生物制药与赛诺菲达成重磅BD合作

Core Viewpoint - China National Pharmaceutical Group announced a global exclusive licensing agreement with Sanofi for the JAK/ROCK inhibitor, Rovaxtinib, which could yield up to $1.53 billion in payments, including an upfront payment of $135 million and potential milestone payments of up to $1.395 billion [1] Group 1 - The agreement allows China National Pharmaceutical Group to receive a tiered royalty based on annual net sales of Rovaxtinib, which is a first-in-class oral small molecule JAK/ROCK inhibitor with dual pathways for anti-inflammatory and anti-fibrotic effects [1] - Rovaxtinib has recently been approved by the National Medical Products Administration for first-line treatment of intermediate-2 or high-risk primary myelofibrosis and PPV-MF in adult patients [1] - The drug has shown excellent efficacy in treating chronic graft-versus-host disease (cGVHD), significantly outperforming existing therapies, and has been recognized as a breakthrough therapy by China's CDE, with clinical trials entering Phase III domestically and FDA approval for Phase II trials in the U.S. [1] Group 2 - Sanofi, a leading multinational pharmaceutical company focused on vaccines, autoimmune diseases, and rare diseases, aligns well with Rovaxtinib's strong performance in the cGVHD treatment area [2] - This collaboration marks a significant step for China National Pharmaceutical Group in its transformation towards becoming an innovative pharmaceutical company, especially following the implementation of centralized procurement policies [3] - The company has been actively expanding its innovative drug business, acquiring companies like Hegia Biotech for $1.2 billion and integrating various innovative drug pipelines across oncology, liver diseases, respiratory, and cardiovascular metabolism [3] Group 3 - The financial performance indicates that the transformation towards innovation is yielding results, with revenue reaching 17.57 billion yuan in the first half of 2025, a year-on-year increase of 10.7%, and innovative product revenue of 7.8 billion yuan, up 27.2%, accounting for over 40% of total revenue [3] - The net profit for the same period was 3.39 billion yuan, reflecting a 140% year-on-year growth, and the company's gross margin has improved to 82.5% [3]